Literature DB >> 26921469

Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.

Tanuja Bordia1, Xiomara A Perez1, Jaime Heiss1, Danhui Zhang1, Maryka Quik1.   

Abstract

L-dopa-induced dyskinesias (LIDs) are a serious complication of L-dopa therapy for Parkinson's disease. Emerging evidence indicates that the nicotinic cholinergic system plays a role in LIDs, although the pathways and mechanisms are poorly understood. Here we used optogenetics to investigate the role of striatal cholinergic interneurons in LIDs. Mice expressing cre-recombinase under the control of the choline acetyltransferase promoter (ChAT-Cre) were lesioned by unilateral injection of 6-hydroxydopamine. AAV5-ChR2-eYFP or AAV5-control-eYFP was injected into the dorsolateral striatum, and optical fibers implanted. After stable virus expression, mice were treated with L-dopa. They were then subjected to various stimulation protocols for 2h and LIDs rated. Continuous stimulation with a short duration optical pulse (1-5ms) enhanced LIDs. This effect was blocked by the general muscarinic acetylcholine receptor (mAChR) antagonist atropine indicating it was mAChR-mediated. By contrast, continuous stimulation with a longer duration optical pulse (20ms to 1s) reduced LIDs to a similar extent as nicotine treatment (~50%). The general nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine blocked the decline in LIDs with longer optical pulses showing it was nAChR-mediated. None of the stimulation regimens altered LIDs in control-eYFP mice. Lesion-induced motor impairment was not affected by optical stimulation indicating that cholinergic transmission selectively regulates LIDs. Longer pulse stimulation increased the number of c-Fos expressing ChAT neurons, suggesting that changes in this immediate early gene may be involved. These results demonstrate that striatal cholinergic interneurons play a critical role in LIDs and support the idea that nicotine treatment reduces LIDs via nAChR desensitization.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ChAT-Cre; ChR2; Dyskinesias; Nicotinic; Optogenetics; Parkinson's disease; Striatum

Mesh:

Substances:

Year:  2016        PMID: 26921469      PMCID: PMC4860059          DOI: 10.1016/j.nbd.2016.02.019

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  85 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry.

Authors:  Alexxai V Kravitz; Benjamin S Freeze; Philip R L Parker; Kenneth Kay; Myo T Thwin; Karl Deisseroth; Anatol C Kreitzer
Journal:  Nature       Date:  2010-07-07       Impact factor: 49.962

3.  Temporal and spatial characteristics of tonically active neurons of the primate's striatum.

Authors:  T Aosaki; M Kimura; A M Graybiel
Journal:  J Neurophysiol       Date:  1995-03       Impact factor: 2.714

4.  Differential effects of the neuropeptide galanin on striatal acetylcholine release in anaesthetized and awake rats.

Authors:  K Antoniou; J Kehr; K Snitt; S O Ogren
Journal:  Br J Pharmacol       Date:  1997-07       Impact factor: 8.739

Review 5.  Molecular basis of levodopa-induced dyskinesias.

Authors:  F Calon; R Grondin; M Morissette; M Goulet; P J Blanchet; T Di Paolo; P J Bédard
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

6.  α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

Authors:  Maryka Quik; Carla Campos; Tanuja Bordia; Jon-Paul Strachan; Jenny Zhang; J Michael McIntosh; Sharon Letchworth; Kristen Jordan
Journal:  Neuropharmacology       Date:  2013-04-12       Impact factor: 5.250

Review 7.  Nicotine and Parkinson's disease: implications for therapy.

Authors:  Maryka Quik; Kathryn O'Leary; Caroline M Tanner
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

8.  Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.

Authors:  Christopher Bishop; David M Krolewski; Karen L Eskow; Christopher J Barnum; Kristin B Dupre; Terrence Deak; Paul D Walker
Journal:  J Neurosci Res       Date:  2009-05-15       Impact factor: 4.164

9.  Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease.

Authors:  Tanuja Bordia; Carla Campos; Luping Huang; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2008-07-23       Impact factor: 4.030

10.  Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons.

Authors:  Sarah Threlfell; Tatjana Lalic; Nicola J Platt; Katie A Jennings; Karl Deisseroth; Stephanie J Cragg
Journal:  Neuron       Date:  2012-07-12       Impact factor: 17.173

View more
  26 in total

Review 1.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

2.  Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.

Authors:  Samira Ztaou; Nicolas Maurice; Jeremy Camon; Gaëlle Guiraudie-Capraz; Lydia Kerkerian-Le Goff; Corinne Beurrier; Martine Liberge; Marianne Amalric
Journal:  J Neurosci       Date:  2016-08-31       Impact factor: 6.167

Review 3.  The striatal cholinergic system in L-dopa-induced dyskinesias.

Authors:  X A Perez; T Bordia; M Quik
Journal:  J Neural Transm (Vienna)       Date:  2018-02-28       Impact factor: 3.575

4.  Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.

Authors:  Xiomara A Perez; Danhui Zhang; Tanuja Bordia; Maryka Quik
Journal:  Mov Disord       Date:  2017-03-03       Impact factor: 10.338

Review 5.  Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Authors:  Carlos Estevez-Fraga; Paul Zeun; Jose Luis López-Sendón Moreno
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

6.  Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.

Authors:  Tanuja Bordia; Danhui Zhang; Xiomara A Perez; Maryka Quik
Journal:  Exp Neurol       Date:  2016-09-19       Impact factor: 5.330

Review 7.  Striatal cholinergic interneurons and Parkinson's disease.

Authors:  Asami Tanimura; Tristano Pancani; Sean Austin O Lim; Cecilia Tubert; Alexandra E Melendez; Weixing Shen; Dalton James Surmeier
Journal:  Eur J Neurosci       Date:  2017-07-20       Impact factor: 3.386

8.  Thalamic degeneration in MPTP-treated Parkinsonian monkeys: impact upon glutamatergic innervation of striatal cholinergic interneurons.

Authors:  Rosa M Villalba; Jean-Francois Pare; Solah Lee; Sol Lee; Yoland Smith
Journal:  Brain Struct Funct       Date:  2019-11-02       Impact factor: 3.270

Review 9.  Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease.

Authors:  Srijan Acharya; Kyeong-Man Kim
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 10.  Adeno-Associated Viral Vectors as Versatile Tools for Parkinson's Research, Both for Disease Modeling Purposes and for Therapeutic Uses.

Authors:  Ana Fajardo-Serrano; Alberto J Rico; Elvira Roda; Adriana Honrubia; Sandra Arrieta; Goiaz Ariznabarreta; Julia Chocarro; Elena Lorenzo-Ramos; Alvaro Pejenaute; Alfonso Vázquez; José Luis Lanciego
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.